Exercise Improves Frailty Scores in Multiple Myeloma
After results presented at IMS 2023 , further evaluation of strength building and walking in patients with multiple myeloma is underway in the Host-Factor study.
Lower PFS Reported For EGFR-mutated Vs EGFR-wildtype NSCLC with Durvalumab
Following PACIFIC-R trial, the ongoing phase 3 LAURA trial is working to evaluate the efficacy and safety of maintenance osimertinib for patients who have unresectable stage III, EGFR-mutated non–small cell lung cancer.
Neoadjuvant Immunotherapy for Stage III Melanoma Emerges as New Standard of Care
The phase 2 SWOG S1801 trial showed a 42% reduction in 2-year event-free survival for neoadjuvant-adjuvant vs adjuvant-only pembrolizumab for resectable stage IIIB-D/IV melanoma.
Ibrutinib Combo Shows Improved Duration of Response in rFL/MZL
The combination of ibrutinib with chemoimmunotherapy improved the duration of response for a subset of patients with relapsed follicular lymphoma and marginal zone lymphoma.
Ivosidenib Granted Priority Review by FDA for IDH1+ R/R Myelodysplastic Syndromes
The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.
2 Clarke Drive Cranbury, NJ 08512